Jounce Therapeutics to Present at Upcoming Investor Conferences in September
29 août 2018 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
02 mai 2018 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
08 mars 2018 06h30 HE
|
Jounce Therapeutics, Inc.
- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC trial in the second quarter of 2018 - - Reiterate 2018 strategy to advance clinical and research pipeline to drive...
Jounce Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference
05 mars 2018 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
28 févr. 2017 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Appoints Perry Karsen to Its Board of Directors
21 janv. 2016 07h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient enrichment,...